NCT04819347 is a Phase 2 clinical trial of Albuvirtide in HIV/AIDS, sponsored by Frontier Biotechnologies Inc..

Who is sponsoring NCT04819347?

NCT04819347 is sponsored by Frontier Biotechnologies Inc..

What drugs are being tested in NCT04819347?

Interventions in NCT04819347: Albuvirtide, 3BNC117.

Is NCT04819347 still recruiting?

NCT04819347 is currently status unknown. Last updated 26 March 2021.

Last reviewed 2021-03-26 · How we verify

NCT04819347

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Status unknown Phase 2 Last updated 26 March 2021

What this trial tests

Phase 2 trial testing Albuvirtide in HIV/AIDS in 24 participants. Status unknown.

Timeline

1 May 2021

Primary endpoint
1 June 2022

1 December 2022

Quick facts

Lead sponsor	Frontier Biotechnologies Inc.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 May 2021
Primary completion	1 June 2022
Estimated completion	1 December 2022
Sites	1 location across China

Drugs / interventions tested

Albuvirtide — full drug profile →
3BNC117 — full drug profile →

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →

Sponsor

Frontier Biotechnologies Inc. — full company profile →

Who can join

18 and older, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression and viral reservoir clearance after analytical treatment interruption (ATI).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD, Corey L, Montefiori D. · · 2021 · cited 34× · PMID 34806308 · DOI 10.1002/jia2.25829
Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.
Mahomed S, Pillay K, Hassan-Moosa R, Galvão BPGV, et al · · 2025 · cited 20× · PMID 40189566 · DOI 10.1186/s12981-025-00734-8
Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.
Monteiro A, Yu KOA, Hicar MD. · · 2021 · cited 14× · PMID 34503415 · DOI 10.2174/1570162x19666210908115231
Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.
Mashhadi Abolghasem Shirazi M, Haghighat S, Nikbakht Z, Salimkia E, et al · · 2025 · PMID 41106780 · DOI 10.1016/j.virusres.2025.199642

Verify or expand the search:

Other trials of Albuvirtide

Trials testing the same drug.

NCT05206019 — Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection · Phase 1 · completed
NCT04560569 — Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection · Phase 2 · unknown

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Frontier Biotechnologies Inc. trials

Trials by the same sponsor.

NCT05583812 — A Study of FB2001 for Inhalation in Healthy Chinese Adults · Phase 1 · completed
NCT05206019 — Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection · Phase 1 · completed
NCT05197179 — A Bridging Study of FB2001 in Healthy Subjects · Phase 1 · completed
NCT04560569 — Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection · Phase 2 · unknown
NCT04766931 — The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04819347 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Frontier Biotechnologies Inc.
Last refreshed: 26 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04819347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing